A novel score to predict in-hospital mortality for patients with acute coronary syndrome and out-of-hospital cardiac arrest: the FACTOR study Clin Res Cardiol . 2024 Feb 8. doi: 10.1007/s00392-023-02367-1. Abstract Introduction : Acute coronary syndromes (ACS) represent a substantial global healthcare challenge. In its most severe form, it can lead to out-of-hospital cardiac arrest (OHCA). Despite medical advancements, survival rates in OHCA patients remain low. Further, the prediction of outcom...
Feb 29, 2024•3 min
Ticagrelor versus Clopidogrel in Endovascular therapy for Cerebral Aneurysms: A Systematic Review and Meta-analysis World Neurosurg . 2024 Feb 9:S1878-8750(24)00210-9 Abstract Background: Antiplatelet therapy is pivotal in endovascular treatment for intracranial aneurysms. However, there is a lack of studies comparing ticagrelor to clopidogrel in patients with aneurysms undergoing endovascular therapy. Additionally, the existing literature lacks adequate sample size, significant subgrouping, and...
Feb 29, 2024•3 min
Factors Associated With Myocardial Infarction in a Rural Population With Peripheral Arterial Diseases Angiology. 2024 Feb 6:33197241232608. doi: 10.1177/00033197241232608. Abstract Peripheral arterial disease (PAD) studies in rural populations are limited. The incidence of myocardial infarction (MI) is higher in patients with PAD. This study examined the association between sociodemographic and clinical risk factors and MI in patients with PAD in Central Appalachia, comprising of 230 countries a...
Feb 29, 2024•2 min
Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guideline Am J Med . 2024 Feb;137(2):137-146.e10. doi:10.1016/j.amjmed.2023.09.021 Abstract Objective: We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendations in a real-world cohort of patients receiving secondary prevention after acute myocardial infarction fr...
Feb 29, 2024•3 min
The Prognostic impact of treatments evolution in STEMI Int J Cardiol. 2024 Jan 1:394:131352. doi: 10.1016/j.ijcard.2023.131352 Abstract Objective: To evaluate in a real-world primary percutaneous coronary intervention (pPCI) registry the impact of the evolution of evidence-based treatments on prognosis. Methods: STEMI patients undergoing pPCI at the University Hospital of Trieste, Italy, were enrolled. The first cohort (old treatments cohort) included STEMI patients treated between January-2007 ...
Jan 31, 2024•3 min
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):11-19. doi: 10.1093/ehjcvp/pvad069 Abstract Aim: To assess the value of the thrombotic risk criteria proposed in the 2023 guidelines of the European Society of Cardiology (ESC) for the management of acute coronary syndrome (ACS) to predict the ischaemic risk after percutaneous coronary intervention...
Jan 31, 2024•3 min
One year clinical outcome of dual anti-platelet therapy with the Novel Ticagrelor plus Aspirin versus Clopidogrel plus Aspirin for Endovascular Intervention of patients with Intracranial Aneurysm: A meta-analysis J Stroke Cerebrovasc Dis. 2024 Jan;33(1):107491. Abstract Background : The use of stents to treat un-ruptured intracranial aneurysms was first approved in the year 2002 in the United States as a Humanitarian Device Exemption. Antiplatelet therapy is mandatory following stent placement. ...
Jan 31, 2024•4 min
Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis Curr Probl Cardiol . 2024 Jan 4:102376. doi:10.1016/j.cpcardiol.2024.102376. Abstract Introduction: While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). To date, the benefit of beta-blockers remains uncertain, and there is ...
Jan 31, 2024•3 min
De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary Syndrome Clin Ther. 2023 Dec 8:S0149-2918(23)00305-3. doi: 10.1016/j.clinthera.2023.08.004 Abstract Purpose: East Asian individuals have a lower risk of thromboembolic events while potentially carrying a higher risk of bleeding events compared with non-Asian individuals. The aim of the present analysis was to investigate the effectiveness and safety of the de-escalation of an...
Dec 31, 2023•3 min
Emergent use of ticagrelor during endovascular reperfusion in large arterial occlusions J Stroke Cerebrovasc Dis . 2023 Dec;32(12):107351. doi: 10.1016/j.jstrokecerebrovasdis.2023 Abstract Objective : Given many emerging indications for endovascular interventions in ischemic strokes, a safe and effective adjuvant antiplatelet regimen for acute revascularization has become a subject of interest. Ticagrelor is a direct oral P2Y12 inhibitor that may achieve rapid platelet suppression than standard ...
Dec 31, 2023•3 min
Effect of beta-blockers and exercise restriction on the prevention of sudden cardiac death in pediatric hypertrophic cardiomyopathy JCardiol. 2023 Dec 2:S0914-5087(23)00288-5. doi: 10.1016/j.jjcc.2023.11.009. Abstract Background: Risk assessment tools and effective prevention strategies for sudden cardiac death (SCD) in pediatric patients with hypertrophic cardiomyopathy (HCM) have not been established. This study aimed to evaluate the efficacy of beta-blockers and exercise restriction for SCD p...
Dec 31, 2023•3 min
Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction ESC Heart Fail. 2023 Dec;10(6):3677-3689. doi: 10.1002/ehf2.14559 Abstract Aims: The use of guideline-directed medical therapy (GDMT) among patients with heart failure (HF) with reduced ejection fraction (HFrEF) remains suboptimal. The SMYRNA study aims to identify the clinical factors for the non-use of GDMT and to determine the prognostic significance of GDMT in patients with HFrEF in a rea...
Dec 31, 2023•4 min
A new meta-analysis of the two trials showed that "oral anticoagulation with edoxaban or apixaban reduces the risk of ischemic stroke by approximately one-third and increases major bleeding by roughly double. In absolute numbers, there were three fewer ischemic strokes per 1000 patient years with anticoagulation in the two trials combined, at the cost of seven more major bleeds. I n patients with pacemakers or implantable loop recorders with continuous monitoring, subclinical AF is detected in a...
Nov 30, 2023•2 min
People who followed a low-salt diet for just a week experienced a reduction in systolic blood pressure of about 6 mm Hg, in a new study. Raised blood pressure contributes to 1 out of every 8 deaths worldwide. "If people want to lower their blood pressure, attention to dietary sodium is one part of that. If individuals can stick with a low sodium diet, they may be able to stop taking one of their antihypertensive medications, and those who are normotensive will be less likely to develop hypertens...
Nov 30, 2023•2 min
Aspirin may not be necessary or beneficial in patients with advanced heart failure who get a left ventricular assist device (LVAD), new randomized results suggest. "We've always thought that somehow aspirin prevents stroke and prevents clotting and that it's anti-inflammatory, and what we found in ARIES was the exact opposite," said Mandeep Mehra, MD, of Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School in Boston, Massachusetts, who reported results of the ARIES-HM3...
Nov 30, 2023•2 min
In patients with myocardial infarction (MI) and anemia, a "liberal" red blood cell (RBC)transfusion strategy significantly reduce the risk of recurrent MI or death within 30 days compared with a "restrictive" transfusion strategy, in the 3500-patient MINT trial. A liberal transfusion strategy may be the most prudent approach to transfusion in anemic patients with MI We cannot claim that a liberal transfusion strategy is definitively superior based on our primary outcome," he said, but "the 95% con...
Nov 30, 2023•2 min
β1-blockers in the reduction of bleeding risk in patients prescribed with potent dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention Hellenic J Cardiol. 2023 Oct 12:S1109-9666(23)00188-4. doi: 10.1016/j.hjc.2023.09.017 Abstract Background: β1-blockers could improve clinical outcomes in patients with coronary artery disease by lowering the heart rate, blood pressure, and myocardial contractility. Moreover, recent studies have suggested that β1-blockers ma...
Oct 31, 2023•3 min
Sex and Age Differences of Major Cardiovascular Events in Patients After Percutaneous Coronary Intervention J Chin Med Assoc . 2023 Oct 10. doi: 10.1097/JCMA.0000000000001011 Abstract Background : Women usually have higher risk after receiving percutaneous coronary interventions (PCIs) than men with coronary artery disease (CAD). The aim of this study was to investigate the association of sex differences with future outcomes in CAD patients undergoing PCI, to assess the role of age, and to exten...
Oct 31, 2023•3 min
Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis J Cardiovasc Pharmacol. 2023 Oct 1;82(4):298-307. doi: 10.1097/FJC.0000000000001460 Abstract Dual antiplatelet therapy with aspirin and P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) has been shown to be associated with better outcomes. Yet, there is uncertainty regarding the optimal timing for its initiation. We performed a systematic revie...
Oct 31, 2023•3 min
Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After PercutaneousCoronary Intervention: A Retrospective Cohort Study J Cardiovasc Pharmacol. 2023 Oct 1;82(4):327-332. doi: 10.1097/FJC.0000000000001461 Abstract To date, no studies have specifically examined the efficacy of P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) exhibiting a high risk of gastrointes...
Oct 31, 2023•3 min
Factors associated with complications in ST-elevation myocardial infarction: a single-center experience BMC Cardiovasc Disord 2023 Sep 19;23(1):468. Abstract Background: ST-elevation myocardial infarction (STEMI) is a major public health problem. This study aimed to determine the prevalence and identify the determinants of STEMI-related complications in the Cardiology Intensive Care Unit of the Sud Francilien Hospital Center (SFHC). Methods : We retrospectively analyzed the data of 315 patients ...
Sep 30, 2023•2 min
Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention Medicine(Baltimore). 2023 Sep 15;102(37):e34974. Abstract Objective: To explore the effects of ticagrelor and clopidogrel dual antiplatelet therapy on the mean platelet volume-to-lymphocyte ratio (MPVLR), maximum amplitude of adenosine diphosphate-induced platelet-fibrin clots (MAADP), and arachidonic acid (AA) inhibit...
Sep 30, 2023•4 min
Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis Circ Cardiovasc Interv. 2023 Sep;16(9):e013242 Abstract Background : Short-term (≤6 months) dual antiplatelet therapy (DAPT) and DAPT de-escalation become attractive for patients with acute coronary syndrome. Methods: A systemic search identified randomized controlled trials that included patients with acute coronary syndrome treated using (1) standard DAPT ...
Sep 30, 2023•4 min
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):526-535. Abstract Background: Guideline recommendations for the treatment of heart failure with mildly reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of randomized trials. Objectives: We investigated predictors of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/A...
Sep 30, 2023•3 min
Prognostic factors in young patients with ST-segment elevation myocardial infarction Coron Artery Dis. 2023 Aug 1;34(5):298-305. Abstract Objective: The prognostic factors of young patients aged ≤40 years with ST-segment elevation myocardial infarction (STEMI) remain unclear. This study explored risk factors that may affect the 1-year prognosis of young STEMI patients by analyzing patient data of baseline, clinical regimen, and secondary prevention. Methods : Baseline and clinical data were coll...
Aug 31, 2023•4 min
Comparative Effectiveness of Long-Term Maintenance Beta-Blocker Therapy After Acute Myocardial Infarction in Stable, Optimally Treated Patients Undergoing Percutaneous Coronary Intervention J Am Heart Asso. 2023 Aug;12(15): e028976 Abstract Background The benefits of long-term maintenance beta-blocker (BB) therapy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) have not been well established. Methods and Results Using the Korean nationwide r...
Aug 31, 2023•3 min
Metoprolol or Verapamil in the Management of Patients With Hypertrophic Cardiomyopathy: A Systematic Review Cureus. 2023 Aug 9;15(8):e43197 Abstract Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease and is a prevalent cause of sudden cardiac death (SCD). This study aims to establish the benefits and therapeutic value metoprolol or verapamil offer to patients who suffer from symptoms caused by HCM, with regard to resolving left ventricular outflow tract obstruction (LVOTO...
Aug 31, 2023•3 min
Early Effects of Ticagrelor Versus Clopidogrel on Peripheral Endothelial Function After Non-ST-Elevation Acute Coronary Syndrome and Assessment of Its Relationship With Coronary Microvascular Function Am J Cardiol. 2023 Aug 15; 201:16-24 Abstract Peripheral endothelial dysfunction is an independent predictor of adverse long-term prognosis after acute coronary syndrome. Data are lacking on the effects of oral P2Y12-inhibitors on peripheral endothelial function in non-ST-elevation acute coronary s...
Aug 31, 2023•4 min
Impact of Diabetes Mellitus on the Benefit of β-Blocker Therapy After Myocardial Infarction Am JCardiol 2023 Jul 1;198:124-132. doi:10.1016/j.amjcard.2023.04.022. Abstract Beta blockers are uniformly recommended for all patients after myocardial infarction (MI), including those with diabetes mellitus (DM). This study assesses the impact of β-blocker type and dosing on survival in patients with DM after MI. A cohort of 6,682 patients in the Outcomes of Beta-blocker Therapy After Myocardial Infarc...
Jul 31, 2023•4 min
Clinical risk factors and outcomes of young patients with acute ST-segment elevation myocardial infarction: a retrospective study Liang et al. BMC Cardiovascular Disorders (2023), https://doi.org/10.1186/s12872-023-03392-8 Abstract Background This study aimed to analysis the clinical characteristics and prognosis of acute STEMI in patients aged ≤ 45 years. Methods Seven hundred and one patients with STEMI from Liaocheng People’s Hospital from January 2018 to March 2021 were included in this stud...
Jul 31, 2023•3 min
